These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21548575)

  • 1. Effects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.
    Benedetti BT; Peterson EJ; Kabolizadeh P; Martínez A; Kipping R; Farrell NP
    Mol Pharm; 2011 Jun; 8(3):940-8. PubMed ID: 21548575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction.
    Peterson EJ; Menon VR; Gatti L; Kipping R; Dewasinghe D; Perego P; Povirk LF; Farrell NP
    Mol Pharm; 2015 Jan; 12(1):287-97. PubMed ID: 25407898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cells.
    Kabolizadeh P; Engelmann BJ; Pullen N; Stewart JK; Ryan JJ; Farrell NP
    J Biol Inorg Chem; 2012 Jan; 17(1):123-32. PubMed ID: 21918844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: differential cellular accumulation mechanisms for platinum.
    Silva H; Frézard F; Peterson EJ; Kabolizadeh P; Ryan JJ; Farrell NP
    Mol Pharm; 2012 Jun; 9(6):1795-802. PubMed ID: 22494465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
    Kasparkova J; Fojta M; Farrell N; Brabec V
    Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
    Kabolizadeh P; Ryan J; Farrell N
    Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.
    Kalayda GV; Jansen BA; Molenaar C; Wielaard P; Tanke HJ; Reedijk J
    J Biol Inorg Chem; 2004 Jun; 9(4):414-22. PubMed ID: 15071768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vitro pharmacological behavior of platinum(II) complexes containing 1,2-diamino-1-(4-fluorophenyl)-2-alkanol ligands.
    Würtenberger I; Angermaier B; Kircher B; Gust R
    J Med Chem; 2013 Oct; 56(20):7951-64. PubMed ID: 24050157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.
    Brown SD; Trotter KD; Sutcliffe OB; Plumb JA; Waddell B; Briggs NE; Wheate NJ
    Dalton Trans; 2012 Oct; 41(37):11330-9. PubMed ID: 22886151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.
    Kalayda GV; Jansen BA; Wielaard P; Tanke HJ; Reedijk J
    J Biol Inorg Chem; 2005 May; 10(3):305-15. PubMed ID: 15824924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H; Cheng Q; Yuan S; Ding X; Liu Y
    Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular pharmacology of polynuclear platinum anti-cancer agents.
    Roberts JD; Peroutka J; Farrell N
    J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines.
    Roberts JD; Peroutka J; Beggiolin G; Manzotti C; Piazzoni L; Farrell N
    J Inorg Biochem; 1999 Oct; 77(1-2):47-50. PubMed ID: 10626353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.